Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1996-1-22
|
| pubmed:abstractText |
Of 500 patients with systemic lupus erythematosus observed at our center, 150 fulfilled criteria for lupus nephritis. Of these 150 patients, 91% were female, and 67% were white. The mean age of onset was 26.2 years, and the mean follow-up duration was 11.7 years. Biopsies (n = 142) performed on 107 patients showed the following World Health Organization (WHO) class distribution: class I, n = 1; class II, n = 13; class III, n = 19; class IV, n = 69; class V, n = 17; class VI, n = 8; and class not determinable, n = 15. Ninety-five patients were nephrotic. Therapeutic intervention courses given to all patients (n = 356) included parenteral (IV) cyclophosphamide (n = 58), high-dose oral steroids (n = 126), pulse steroids (n = 49), apheresis (n = 39), azathioprine (n = 43), oral cyclophosphamide (n = 5), nitrogen mustard (n = 27), and chlorambucil (n = 6). In addition to examining the course of disease for various subsets, various predictors for fatality and end-stage renal disease (ESRD) were analyzed. Descriptive data for the short-term response to five therapies are provided for the complete patient sample, proliferative disease, and nephrotic syndrome. Twenty patients died, primarily from cardiovascular complications and sepsis, with 97% and 92% 5- and 10-year survival rates, respectively. Twenty-nine were dialyzed, and 11 were transplanted. Risk of ESRD by WHO class at 5 years was as follows: class III, 0%; IV, 9%; V, 16% (P = .04 for class V v other patterns).(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Azathioprine,
http://linkedlifedata.com/resource/pubmed/chemical/Chlorambucil,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mechlorethamine,
http://linkedlifedata.com/resource/pubmed/chemical/Steroids
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0049-0172
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
47-55
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8525390-Adult,
pubmed-meshheading:8525390-Anti-Inflammatory Agents,
pubmed-meshheading:8525390-Azathioprine,
pubmed-meshheading:8525390-Biopsy,
pubmed-meshheading:8525390-Blood Component Removal,
pubmed-meshheading:8525390-Chlorambucil,
pubmed-meshheading:8525390-Cyclophosphamide,
pubmed-meshheading:8525390-Disease-Free Survival,
pubmed-meshheading:8525390-Female,
pubmed-meshheading:8525390-Follow-Up Studies,
pubmed-meshheading:8525390-Humans,
pubmed-meshheading:8525390-Immunosuppressive Agents,
pubmed-meshheading:8525390-Kidney Failure, Chronic,
pubmed-meshheading:8525390-Lupus Nephritis,
pubmed-meshheading:8525390-Male,
pubmed-meshheading:8525390-Mechlorethamine,
pubmed-meshheading:8525390-Retrospective Studies,
pubmed-meshheading:8525390-Steroids,
pubmed-meshheading:8525390-Survival Rate,
pubmed-meshheading:8525390-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center.
|
| pubmed:affiliation |
Department of Medicine, Cedars Sinai Medical Center, University of California, Los Angeles, USA.
|
| pubmed:publicationType |
Journal Article
|